For more information about upcoming webinars, please see the ACT Education page!
The Accelerating Clinical Trials (ACT) Consortium recently held a competition to bring high-impact randomized controlled trials to Canada that were initiated and are led by
International review panel selects CanReview to set up, initiate, and conduct a pan-Canadian single REB review and approval process with strict timelines. The Accelerating Clinical
Click here for a full summary of the ACT October Meeting In preparation for the Third ACT Consortium Meeting, we are seeking Canadian biotechnology companies
New pan-Canadian data and sample transfer agreement a game-changer for clinical research “We’ve built a high-speed legal highway for researchers to use to share their
For more information about upcoming webinars, please see the ACT Education page!
At the ACT-AEC First Annual Meeting, ACT-AEC invited 48 Canadian biotechnology companies to present their work to members of the consortium. ACT-AEC is proud to
The Accelerating Clinical Trials Consortium is generously supported through multi-year funding from the Canadian Institutes of Health Research’s Clinical Trials Fund, as part of Canada’s Biomanufacturing and Life Sciences Strategy to ensure that Canadians are well served by a national clinical trials network.